Clene Inc.CLNNEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Clene Inc. is a clinical-stage biopharmaceutical company that develops novel neuroprotective therapeutics to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), multiple sclerosis, and Parkinson’s disease. It operates primarily in the U.S. market, focusing on advancing its small molecule candidate pipeline through clinical trials to address unmet medical needs.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Chidozie Ugwumba | 19.90% | 2.2M | flat | 2024-10-02 |
| Nos. of | 9.20% | 12.7M | flat | 2024-11-14 |
| Armistice Capital, LLC | 8.77% | 700.0K | — | 2024-11-14 |
| David J. Matlin | 8.70% | 718.2K | ▲ +3.10pp | 2024-10-02 |
| Vivo | 7.00% | 12.5M | ▼ -2.99pp | 2024-02-13 |
| Citadel Advisors LLC | 4.30% | 134.2M | ▼ -1.40pp | 2024-02-14 |
Insider Transactions
Net 90d: −$1.43M · buys $0 / sells $1.43MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-21 | Chidozie Ugwumba | 10% Owner | Sell (open market) | 61.3K | $6.14 | $376.7K |
| 2026-04-20 | Chidozie Ugwumba | 10% Owner | Sell (open market) | 4.3K | $6.12 | $26.4K |
| 2026-04-17 | Chidozie Ugwumba | 10% Owner | Sell (open market) | 25.0K | $6.43 | $161.0K |
| 2026-04-16 | Chidozie Ugwumba | 10% Owner | Sell (open market) | 7.7K | $6.40 | $49.6K |
| 2026-04-15 | Chidozie Ugwumba | 10% Owner | Sell (open market) | 6.4K | $6.48 | $41.3K |
| 2026-04-02 | Chidozie Ugwumba | 10% Owner | Sell (open market) | 24.9K | $4.81 | $119.9K |
| 2026-04-01 | Chidozie Ugwumba | 10% Owner | Sell (open market) | 4.3K | $4.97 | $21.3K |
| 2026-03-31 | Chidozie Ugwumba | 10% Owner | Sell (open market) | 68.0K | $4.88 | $331.8K |
| 2026-03-30 | Chidozie Ugwumba | 10% Owner | Sell (open market) | 15.5K | $5.10 | $79.2K |
| 2026-03-27 | Chidozie Ugwumba | 10% Owner | Sell (open market) | 17.5K | $4.75 | $83.0K |
1–10 of 15
Page 1 / 2